

Amaxa™ HT Nucleofector™ optimization protocol for primary cells

For use with plasmid DNA and/or siRNA

The primary cell optimization HT Nucleofector™ kit (V5SP-9001) enables you to optimize Nucleofection™ conditions for a primary cell of your choice. This kit is suitable both for optimizing Nucleofection™ of plasmid DNA, as well as, siRNA oligonucleotides.

Overview

Step 1

The primary cell of interest is transfected with the HT Nucleofector™ solutions P1, P2, P3, P4 and P5 in combination with 63 different Nucleofector™ programs plus negative control.

Step 2

The HT Nucleofector™ solution and program which result in highest transfection efficiency with lowest mortality are selected.

Step 3 (optional)

A further fine tuning of the Nucleofection™ conditions can be performed with the help of our scientific support team.

Product description

Cat. No.	V5SP-9001
Size (reactions)	1x384
P1 Primary cell HT Nucleofector™ solution	2.25 ml
P2 Primary cell HT Nucleofector™ solution	2.25 ml
P3 Primary cell HT Nucleofector™ solution	2.25 ml
P4 Primary cell HT Nucleofector™ solution	2.25 ml
P5 Primary cell HT Nucleofector™ solution	2.25 ml
Supplement	3x0.5 ml
pmaxGFP™ vector (1.0 µg/µl in 10 mM Tris pH 8.0)	150 µg
Nucleocuvette™ plate(s)	1

Storage and stability


Store Nucleofector™ solution, supplement and pmaxGFP™ vector at 4°C. For long-term storage, pmaxGFP™ vector is ideally stored at -20°C. The expiry date is printed on the solution box. Once the Nucleofector™ supplement is added to the Nucleofector™ solution, it is stable for three months at 4°C.

Note

HT Nucleofector™ solutions can only be used with conductive polymer cuvettes, i.e. in the HT-Nucleofector™, the 96-well Shuttle™ device and in the 4D-Nucleofector™ system. They are not compatible with the Nucleofector™ II/2b device.

General considerations

Optimal Nucleofection™ conditions are substrate independent, meaning that siRNA oligonucleotides and plasmid DNA can be transfected using the same protocol. This has been confirmed by comparing conditions for plasmid DNA and labelled siRNA.



Nucleofection™ conditions optimized with pmaxGFP™ vector are also optimal for siRNA. Alternatively to pmaxGFP™ vector, you could use fluorescently labelled siRNA. However, microscopic evaluation of fluorescently labelled siRNA is often hampered by rapid photobleaching of the fluorophore. Analysis 4–6 hours post Nucleofection™ recommended.

Optimization guidelines

Step 1

The first experiment is comprised of 320 reactions. Five different primary cell HT Nucleofector™ solutions (P1–P5) are tested in combination with 63 different Nucleofector™ programs plus 1 control for each solution. The HT Nucleofector™ solution and program with the highest efficiency and lowest mortality are selected. For further transfections of plasmid DNA or siRNA, order the respective primary cell HT Nucleofector™ kit (P1–P5) and use it in combination with the selected program

Step 2 (optional)

To maximize Nucleofection™ efficiency, a second experiment based on the best results obtained can be performed. You can test an extended range of cell numbers or DNA amounts per sample or further programs. For this purpose submit your complete results to our scientific support team and within one workday we will suggest additional programs to be tested in combination with the best Nucleofector™ solution. This additional experiment requires purchase of the respective primary cell HT Nucleofector™ kit.

Required material

Note

Please make sure that the entire supplement is added to the Nucleofector™ solution.

- HT Nucleofector™ system
- Supplemented HT Nucleofector™ solutions at room temperature
- Supplied 384-well Nucleocuvette™ plate(s)
- Supplied pmaxGFP™ vector, stock solution 1 µg/µl

Note

Volume of substrate solution added to each sample should not exceed 10 % of the total reaction volume (2 µl for 20 µl reactions). For positive control using pmaxGFP™ vector, please dilute the stock solution to reach the appropriate working concentration.

- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260 : A280 ratio should be at least 1.8
- 96-well culture plates or culture plates of your choice
- 384-well Nucleocuvette™ plates are best handled with an automated liquid handling system. If manual pipetting is required please use compatible tips: epT.I.P.S. (US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266), Matrix TallTips™ (Matrix Technologies Corp., Cat. No. 7281) or LTS Tips (Rainin Instrument, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S). Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ wells without getting stuck
- For detaching adherent cells: For commercially available primary cells we recommend the Reagent™ subculture reagents [Lonza cat. No. CC-5034] or trypsin/EDTA and stop the trypsinization with supplemented culture medium respectively PBS with 0.5% BSA
- Culture medium: For commercially available primary cells we recommend following the instructions of the supplier regarding culture medium and supplements
- Recovery medium (optional for adherent cells): For cells grown in high-calcium medium, such as Dulbecco's Modified Eagle Medium (DMEM), you may use a low calcium medium, like RPMI, for the transfer from the cuvette into the plate (see chapter 2, note after 2.16)
- Pre-warm appropriate volume of culture medium to 37°C (60 µl per sample for suspension cells; 60 µl per sample for adherent cells)
- Appropriate number of cells (0.2–1x10⁶ per sample for suspension cells; 1–5x10⁵ cells per sample for adherent cells; lower or higher cell numbers may influence transfection results)

1. Pre Nucleofection™

Note

For commercially available primary cells we recommend following the instructions of the supplier regarding media renewal, passaging and seeding conditions. Best Nucleofection™ results will be obtained with standardized cell culture conditions.

Cell culture recommendations for adherent cells

- 1.1 Subculture 1–2 days before Nucleofection™
- 1.2 Optimal confluency for Nucleofection™: 70–85 %. Higher cell densities may cause lower Nucleofection™ efficiencies

Cell culture recommendations for suspension cells

- 1.3 Subculture 1–2 days before Nucleofection™
- 1.4 Optimal density for Nucleofection™: cells must be in their logarithmic growth phase

Trypsinization (for adherent cells only)

- 1.5 For commercially available primary cells we recommend following the instructions of the supplier regarding detaching of cells. You may e.g. use trypsin/EDTA and stop the trypsinization with supplemented culture medium or PBS/0.5 % BSA

2. Nucleofection™

One Nucleofection™ sample contains

- 0.2–1x10⁶ cells (suspension cells) or 1–5x10⁵ cells (adherent cells)
- 0.4 µg pmaxGFP™ vector
- 20 µl P1–P5 Primary cell HT Nucleofector™ solutions

Note

The volumes and cell numbers indicated below refer to the exact numbers required for the experiment. Please include sufficient extra volume and cells when setting up your pipetting scheme to account for possible losses during pipetting or small discrepancies in pipetted volumes (which may arise from inexactly calibrated pipettes or loose pipette tips).

- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ solution
- 2.2 Start HT Nucleofector™ software, verify device connection and generate parameter file from predefined template for primary cell optimization (for details refer to the HT Nucleofector™ manuals)
- 2.3 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media and pre-incubate/equilibrate plates in a humidified 37°C/5 % CO₂ incubator
 - Adherent cells: 185 µl per well*
 - Suspension cells: 170 µl per well*(*see note at the end of this chapter)

- 2.4 Pre-warm an aliquot of culture medium to 37°C (40 µl per sample)
- 2.5 Optional (adherent cells): Harvest the cells by trypsinization (please see 1.5)
- 2.6 Count an aliquot of the cells and determine cell density
- 2.7 Prepare three aliquots of cell suspension, each with the number of cells required for 64 samples (one aliquot for each well Nucleofector™ solution and both types of siRNA, see optimization guidelines)
- 2.8 Centrifuge the required number of cells at 90xg for 10 minutes at room temperature. Remove supernatant completely
- 2.9 Resuspend each cell pellet in room temperature HT Nucleofector™ solution to a final concentration of:
 - Suspension cells: 2×10^5 – 1×10^6 cells/20 µl
 - Adherent cells: 1×10^5 – 5×10^5 cells/20 µl
- 2.10 Mix each cell suspension with the appropriate amount of pmaxGFP™ vector
- 2.11 Transfer 20 µl of each of the 3 aliquots into 64 wells of the 384-well Nucleocuvette™ plate, according to the experimental setup (see optimization guidelines)

Note

It is advisable to pre-dispense each cell suspension into a sterile round-bottom 384-well plate or to pipet from a pipetting reservoir for multi-channel pipettes. Use a multi-channel or single-channel pipette with suitable pipette tips. As leaving cells in HT Nucleofector™ solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.12 Briefly shake the 384-well Nucleocuvette™ plate with an appropriate microtiter plate shaker to make sure the sample covers the bottom and the sides of the wells without air bubbles. Alternatively thoroughly tap the 384-well Nucleocuvette™ plate
- 2.13 Place 384-well Nucleocuvette™ plate with closed lid onto the carousel of the plate handler of the HT Nucleofector™. Well “A1” must be in upper left position
- 2.14 Start Nucleofection™ process clicking “Start” in the HT Nucleofector™ software (for details refer to the HT Nucleofector™ manuals)
- 2.15 After run completion, carefully remove the 384-well Nucleocuvette™ plate from the carousel
- 2.16 Resuspend cells with desired volume of pre-warmed culture medium (maximum cuvette volume 60 µl). Mix cells by gently pipetting up and down two to three times. Recommendation for 96-well plates: Resuspend cells in 40 µl of pre-warmed media*
- 2.17 Plate desired amount of cells in culture system of your choice. Recommendation for 96-well plates: Transfer 15 µl for adherent cells respectively 30 µl for suspension cells of resuspended cells to 185 µl for adherent cells respectively 170 µl for suspension cells pre-warmed media

Note

If very high mortality is observed, a “recovery step” can be a useful option: Immediately after Nucleofection™, add 80 µl pre-equilibrated low-calcium media such as RPMI and gently transfer it to the reaction tube. Place the cell suspension in an incubator for 5–10 minutes. Then transfer the sample to the prepared culture dish with culture medium.

* Note

The indicated cell numbers and volumes have been found to produce optimal Nucleofection™ results in most cases. However, depending on your specific needs you may wish to test an extended range of cell numbers. Cell numbers and volumes can be adapted such that fewer cells are transferred or duplicate plates can be seeded.

3. Post Nucleofection™

- 3.1 Incubate the cells in humidified 37°C/5% CO₂ incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4–8 hours. A usual analysis time is 24 hours post Nucleofection™

Additional information

Up-to-date list of all Nucleofector™ references

www.lonza.com/nucleofection-citations

Technical assistance and scientific support

USA/Canada

Tel 800 521 0390 (toll-free)

Fax 301 845 8338

scientific.support@lonza.com

Europe and Rest of World

Tel + 49 221 99199 400

Fax + 49 221 99199 499

scientific.support.eu@lonza.com

www.lonza.com

Lonza Cologne GmbH–50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector™ technology, comprising Nucleofection™ process, Nucleofector™ device, Nucleofector™ solutions, Nucleofector™ 96-well Shuttle™ system, 96-well Nucleocuvette™ plates and modules, HT Nucleofector™ and 384-well Nucleocuvette™ plates is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Falcon is a trademark of BD Biosciences.

Ficoll Paque is a trademark of GE Healthcare.

FACSCalibur is a trademark of Becton Dickinson.

TallTips are a registered trademark of Matrix Technologies Corporation.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN.

To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtaining of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.